PBLA News and Press, Panbela Therapeutics Inc Com From 12/14/22

MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pa nbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for ...

MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced its first patients enrolled in Europe for its ASPIRE ...

Panbela Therapeutics, Inc. (PBLA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - CEO Susan Horvath - CFO Conference Call Participants Tony Butler - ROTH Capital P...

Panbela Therapeutics press release ( NASDAQ: PBLA ): Q3 GAAP EPS of -$0.21. Total cash was $0.9 million as of September 30, 2022. Total current assets were $1.8million and current liabilities were $8.0 million as of the same date. For further details see: Panbela...

MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the qu...

MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com Pre-market stock movers continue to be a major topic as we dive into the latest news investors need to know about on Friday! Moving stocks are a reverse split, earnings reports,...

Panbela Therapeutics (NASDAQ: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has released the pricing of its public offering. The public offering is comprised of 20,100,000 shares of its common stock (or pre...

MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced today that management will participate in the inaugural Ro...

Panbela Therapeutics ( NASDAQ: PBLA ) prices a public offering of (i) 20.1M shares of stock, warrants to purchase up to 30.15M shares at a purchase price of $0.30. Warrants will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five ...